Prediction of Visual Field Progression in Patients with Primary Open-Angle Glaucoma, Mainly Including Normal Tension Glaucoma

Nitta K., Wajima R., Tachibana G., Inoue S., Ohigashi T., Otsuka N., Kurashima H., Santo K., Hashimoto M., Shibahara H., Hirukawa M., Sugiyama K.

2017
Scientific Reports

View publication

Therapeutic Area

Glaucoma
Categories

Post-Approval studies/RWE

Affiliations

Fukui-ken Saiseikai Hospital, Fukui, Japan; Kanazawa University Graduate School of Medical Science, Kanazawa, Japan; Crecon Medical Assessment Inc., Tokyo, Japan; Santen Pharmaceutical Co. Ltd., Osaka, Japan

Related Publications

Long-term safety and efficacy of sepetaprost, with or without timolol, in patients with open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J2 study

Inatani M., Tone Y., Ikeda T., Angeles R.

Efficacy and safety of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J1 study

Inatani M., Kanamori A., Inai M., Ikeda T., Angeles R.

Clinical outcomes of Preserflo MicroShunt implant procedure in open‑angle glaucoma patients – a 1000 eyes case-series; including subanalysis of combined cataract-glaucoma surgery and standalone surgery in pseudophakic eyes

Klabe, K.; Werth, J.P.; Kaymak, H. ; Fricke, A.

View all Glaucoma publications

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022